SPX Corporation
SPXC
$167.26
+1.25%
SPX Technologies, Inc. is a diversified industrial manufacturer that supplies engineered HVAC products—including cooling towers, heating and ventilation equipment—alongside detection and measurement technologies such as underground pipe and cable locators, inspection equipment, and bus-fare collection systems, operating primarily in the United States with additional footprint in Canada, China, and the UK. The company is best characterized as a focused niche industrial compounder rather than a broad-based materials player, with its HVAC segment generating the majority of revenue and its Detection & Measurement segment providing a complementary, higher-margin technology layer. The current investor narrative centers on a sharp disconnect between strong operating execution and a collapsing share price: revenue grew 22.9% year-over-year in the most recent quarter to $679 million with expanding operating margins, yet the stock has fallen roughly 28% over six months and 16% over the past year, suggesting the market is pricing in concerns about the durability of HVAC demand, the integration of recent acquisitions (roughly $440 million deployed in Q1 2026), and a broader de-rating of cyclical industrial names. Management's aggressive M&A posture and rising leverage have become the central debate, with bulls pointing to double-digit organic growth and margin expansion and bears questioning whether the acquisition-driven growth model can sustain its returns as the cycle matures.…
SPXC
SPX Corporation
$167.26
Investment Opinion: Should I buy SPXC Today?
Rating: Hold with a speculative accumulation bias. The core thesis is that a genuine disconnect exists between strong operating execution — 22.9% revenue growth, 17.2% operating margin, $303.4M TTM free cash flow — and a stock trading 58% below its $253.38 average analyst target with a 'strong buy' consensus (mean 1.21 across 13 analysts), but the accelerating downtrend and proximity to the 52-week low argue against chasing a falling knife before evidence of a bottom.
Supporting evidence is substantial: revenue grew 22.9% YoY to $679.0M with operating margin up 150bps to 17.2%, net margin improved from 9.4% to 11.5%, gross margin held at 40.2%, and the forward PE of 16.4x is below the broader market versus a 39.2x trailing multiple. Debt-to-equity of 0.224 and interest coverage of 13.25x confirm balance-sheet health, and the $215 low analyst target still implies 34% upside. However, PS of 4.22x, EV/EBITDA of 20.0x, and PEG of 2.24 show the stock is not cheap on trailing or growth-adjusted terms, and the -34.5% six-month relative underperformance versus SPY is a powerful counterweight.
The biggest risks that could invalidate the thesis are (1) a cut to the $9.58 consensus EPS if HVAC demand or acquisition integration disappoints, (2) a break below the $155.86 52-week low triggering momentum-driven selling, and (3) rising leverage from continued M&A. This Hold would upgrade to Buy if the stock reclaims the $170–$175 resistance zone on a Q3 beat with reaffirmed guidance, or if the forward PE compresses below 14x on stable estimates; it would downgrade to Sell on a break below $155.86 or evidence of organic growth decelerating below 10%. Verdict: fairly valued on forward earnings, expensive on trailing fundamentals — a show-me story rather than a clear bargain.
Sign up to view all
SPXC 12-Month Price Forecast
The forward-looking view is genuinely balanced: operating fundamentals are strong and improving, but the market is pricing in risks the sell-side has not acknowledged, and the technical picture is unambiguously negative. The 16.4x forward PE is the fulcrum — if the $9.58 consensus EPS is achieved, the stock is cheap relative to its own history and the broader market; if it is cut, the 39.2x trailing PE and 4.22x PS offer no support. With the stock 2.9% above its 52-week low and momentum accelerating downward, the risk/reward is asymmetric only for patient investors willing to wait for a bottoming signal. I would upgrade to bullish on a reclaim of $175 with a Q3 beat and reaffirmed guidance, and downgrade to bearish on a decisive break below $155.86 or evidence of organic growth below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on SPX Corporation's 12-month outlook, with a consensus price target around $250.69 and implied upside of +49.9% versus the current price.
Average Target
$250.69
0 analysts
Implied Upside
+49.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$215 - $310
Analyst target range
Coverage is robust, with 13 analysts and a consensus recommendation of "strong buy" (mean rating of 1.21 on a 1–5 scale where 1 is a strong buy). The average target price of $253.38 implies roughly 58% upside from the current $160.33—an unusually large gap that signals either a significant mispricing opportunity or analyst estimates that have not yet caught up with the deteriorating price action. The consensus is decisively bullish, and the recent institutional ratings show a pattern of reiterations rather than downgrades: Truist (Buy), B. Riley (Buy), Oppenheimer (Outperform), JP Morgan (Overweight), and Wells Fargo (Overweight) have all maintained positive ratings through 2026, with Truist notably upgrading from Hold to Buy in March 2026. The absence of any recent downgrade despite a 28% six-month decline is a meaningful signal that the sell-side views this as a valuation disconnect rather than a fundamental deterioration.
The target range of $215 to $310 is wide—a 44% spread between low and high—indicating high uncertainty about the growth trajectory. The high target of $310 would require multiple expansion back toward the 52-week high and confidence that the $9.58 consensus EPS is achievable, implying a forward PE of roughly 32x at that price; the low target of $215 still represents 34% upside and likely assumes some estimate haircut and a more modest re-rating. The consensus revenue estimate of $2.82 billion (range $2.72–$2.89 billion) and EPS range of $9.14–$9.90 suggest analysts expect continued double-digit growth. The key risk is that the stock's 58% discount to the average target reflects a market that is pricing in something the analysts are not—whether HVAC cycle concerns, acquisition integration risk, or leverage—and until the price stabilizes above the $170–$175 resistance zone, the wide target spread should be treated as a warning sign of conviction gaps rather than a pure upside opportunity.
Drowning in data?
Find the real signal!
Bulls vs Bears: SPXC Investment Factors
The bear case currently has stronger near-term evidence: the stock is in an accelerating downtrend (-27.1% over three months, -34.5% relative to SPY over six months), sits 2.9% above its 52-week low, and trades at a 39.2x trailing PE near the top of its historical range despite the collapse. The bull case rests on genuinely strong fundamentals — 22.9% revenue growth, operating margin expansion to 17.2%, low leverage, and a 58% gap to analyst targets — but the market is clearly discounting those numbers. The single most important tension is whether the $9.58 consensus forward EPS is achievable: at a 16.4x forward PE the stock is cheap, but if HVAC demand or acquisition integration disappoints, both the multiple and the estimate can compress simultaneously in a dangerous double-hit. Resolution likely comes at the next earnings print — a beat with reaffirmed guidance would validate the disconnect, while a miss would confirm the market's skepticism.
Bullish
- Revenue accelerating at 22.9% YoY: Q2 2026 revenue of $679.0M grew 22.9% from $552.4M, following +17.4% in Q1 2026 and +19.4% in Q4 2025 — four straight quarters of high-teens-to-low-20s growth. Even after stripping out the ~$439.6M of Q1 2026 acquisitions, the organic base is clearly expanding.
- Operating margin expansion to 17.2%: Q2 2026 operating margin of 17.2% rose from 15.7% in Q2 2025 and 13.8% in Q1 2025, while gross margin held steady at 40.2% within a tight 39.8%–41.4% band over eight quarters. Net margin improved from 9.4% to 11.5% YoY, showing genuine operating leverage.
- 58% upside to analyst average target: The $253.38 average target implies ~58% upside from $160.33, with a consensus 'strong buy' (mean 1.21 across 13 analysts) and no downgrades despite a 28% six-month decline. The $215 low target still implies 34% upside, suggesting the sell-side views this as a valuation disconnect.
- Forward PE of 16.4x vs 39.2x trailing: Consensus EPS of $9.58 versus the depressed trailing base creates a 58% multiple compression, putting the forward PE below the broader market. If estimates prove achievable, the stock is cheap on forward earnings despite looking expensive on trailing fundamentals.
Bearish
- Stock at 16.8% of 52-week range: At $160.33 the stock sits just 2.9% above its $155.86 52-week low and 36.1% below the $251.08 high, with a -35.06% max drawdown. The pattern of lower highs and lower lows since the June peak near $246 is textbook distribution, and a break below $155.86 opens the door to new lows.
- Severe and accelerating relative weakness: The stock is down 27.1% over three months and 28.0% over six months while SPY gained 2.85% and 6.45% respectively — relative strength of -30.0% and -34.5%. The 1-month change of -7.6% shows the decline is accelerating, not stabilizing.
- Trailing PE of 39.2x near historical top: The 39.2x trailing PE sits near the top of the stock's own 19x–41x historical band even after the price collapse, and PEG of 2.24 shows it is not cheap on growth-adjusted terms. PS of 4.22x and EV/EBITDA of 20.0x are elevated for a mid-cycle industrial.
- Acquisition-driven growth and rising leverage: Roughly $439.6M of Q1 2026 acquisitions funded partly by debt, a $207.7M net cash decrease, and a $34.1M working-capital drag on Q2 FCF mean growth is increasingly inorganic. Investors must question whether the M&A model sustains returns as the HVAC cycle matures.
SPXC Technical Analysis
SPX Technologies is in a pronounced, sustained downtrend. The stock has fallen 15.79% over the past year and 21.12% year-to-date, and at $160.33 it sits just 2.9% above its 52-week low of $155.86 and 36.1% below its 52-week high of $251.08—trading at roughly 16.8% of its 52-week range, a positioning that signals persistent selling pressure rather than a value floor. The pattern of lower highs and lower lows since the June peak near $246 is textbook distribution, and the proximity to the 52-week low means the stock is a falling knife until proven otherwise; a decisive break below $155.86 would open the door to new lows with little technical support beneath.
Short-term momentum is uniformly negative and, critically, deteriorating faster than the long-term trend. The 1-month change of -7.64% and 3-month change of -27.15% show acceleration in the decline, while the 6-month change of -28.05% confirms the damage is not a brief pullback. Relative strength is deeply negative across every window—-6.62% versus SPY over one month, -30.00% over three months, and -28.92% over one year—meaning the stock is underperforming a market that itself gained 13.13% over the past year. The most recent price action (from $168.13 on October 21 to $160.33 on October 23) shows the selling reasserting itself after a brief stabilization attempt, and with volume at 918,261 shares and a short ratio of 3.25, there is no evidence of capitulation or short-covering support.
Key technical levels are starkly defined: support sits at the 52-week low of $155.86, just 2.8% below the current price, while resistance is layered at the $170–$175 area (the October consolidation zone) and then the $187–$200 region where the July breakdown occurred. A breakdown below $155.86 would likely trigger momentum-driven selling and confirm the downtrend's continuation, whereas a reclaim of $175 would be the first meaningful sign of a bottoming process. With a beta of 1.241, the stock is roughly 24% more volatile than the market, and the maximum drawdown of -35.06% over the period illustrates the risk of position sizing into a name with this volatility profile; the 52-week range of $155.86 to $251.08 represents a 61% spread, underscoring how violently sentiment has swung.
Beta
1.24
1.24x market volatility
Max Drawdown
-35.1%
Largest decline past year
52-Week Range
$156-$251
Price range past year
Annual Return
-16.4%
Cumulative gain past year
| Period | SPXC Return | S&P 500 |
|---|---|---|
| 1m | -2.0% | +0.7% |
| 3m | -23.8% | +3.0% |
| 6m | -19.6% | +6.8% |
| 1y | -16.4% | +11.9% |
| ytd | -17.7% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SPXC Fundamental Analysis
The revenue trajectory remains genuinely strong and is accelerating, which makes the stock's collapse all the more notable. Q2 2026 revenue of $679.0 million grew 22.9% year-over-year versus $552.4 million in Q2 2025, following Q1 2026 revenue of $566.8 million (up 17.4% from $482.6 million) and Q4 2025 revenue of $637.3 million (up 19.4% from $533.7 million)—a clear pattern of high-teens to low-20s growth across four consecutive quarters. The Detection and Measurement segment contributed $485.8 million, but the HVAC segment remains the majority revenue driver per the company description. This growth is partly inorganic, given the roughly $439.6 million of acquisitions in Q1 2026, so investors must distinguish organic momentum from acquired revenue; nonetheless, the consistency of the top-line acceleration supports the bull case that end-market demand for HVAC and infrastructure detection equipment remains robust.
Profitability is solid and margins are expanding at the operating line. Q2 2026 net income was $78.4 million (11.5% net margin) on gross profit of $272.8 million (40.2% gross margin), with operating income of $116.6 million and an operating margin of 17.2%—up from 15.7% in Q2 2025 and 13.8% in Q1 2025. Gross margin has been remarkably stable in the 39.8%–41.4% band over eight quarters, while EBITDA margin improved to 21.6% in Q2 2026 from 21.4% a year earlier, and net margin rose from 9.4% to 11.5%. The company is clearly profitable with a trailing EPS of $0.0255 (reflecting a recent share-count or accounting distortion) but a quarterly diluted EPS of $1.55, and the 40.5% gross margin is consistent with a differentiated industrial manufacturer rather than a commodity materials producer. The margin story is one of steady operational leverage, not dramatic re-rating.
Balance sheet health is good but leverage is rising due to the acquisition strategy. Debt-to-equity stands at a modest 0.224, the current ratio is a healthy 2.48, and interest coverage is 13.25x, while TTM free cash flow of $303.4 million represents a 3.2% FCF yield on the $9.57 billion market cap. However, the Q1 2026 cash flow statement shows $439.6 million of acquisitions funded partly by $172.2 million of debt repayment activity and a $207.7 million net cash decrease, and Q2 2026 FCF of $68.5 million was dampened by a $34.1 million working capital drag. ROE of 10.9% and ROA of 6.8% are respectable but not exceptional, and the $28.7 price-to-cash-flow ratio signals the market is paying dearly for that cash generation. The company can fund growth internally, but the M&A cadence means external financing remains part of the model.
Quarterly Revenue
$679000000.0B
2026-06
Revenue YoY Growth
+22.9%
YoY Comparison
Gross Margin
40.2%
Latest Quarter
Free Cash Flow
$303400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SPXC Overvalued?
Because net income is positive ($78.4 million in Q2 2026), the PE ratio is the appropriate primary metric. The trailing PE of 39.2x compares with a forward PE of 16.4x—an enormous 58% compression that implies the market expects earnings to more than double, consistent with consensus EPS estimates of $9.58 versus the trailing figure. That gap is the crux of the valuation debate: either the forward estimate is achievable and the stock is cheap on a forward basis, or the trailing multiple reflects genuine overvaluation and estimates are too optimistic. The PEG ratio of 2.24 suggests that even on growth-adjusted terms, the stock is not inexpensive.
Against the sector, the stock screens at a premium on most measures. The PS ratio of 4.22x and EV/Sales of 3.42x are elevated for a construction-materials/industrial name, and the EV/EBITDA of 20.0x is well above what a mid-cycle industrial typically commands. The PB ratio of 4.28x and price-to-cash-flow of 28.7x reinforce that the market has historically awarded SPX a growth premium. However, the forward PE of 16.4x is actually below the broader market multiple, creating a stark bifurcation: on trailing fundamentals the stock is expensive, but on forward earnings it looks reasonably valued—a classic setup where the market is either mispricing the stock or doubting the estimates.
Historically, SPX's own valuation band tells a cautionary tale. The PE ratio has ranged from roughly 19x (Q1 2023) to over 41x (Q1 2026), and the current 39.2x trailing PE sits near the top of that historical range even after the price decline—because earnings estimates have been cut or the trailing base is depressed. The PS ratio of 4.22x is actually below the 17.1x seen in Q2 2026 historical data (which appears to use a different share/revenue base), but on a like-for-like basis the stock's current multiples are mid-to-high within its own history. The market is pricing in optimistic forward expectations, and the risk is that if the HVAC cycle or acquisition integration disappoints, both the multiple and the estimate can compress simultaneously—a dangerous double-hit scenario.
PE
39.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the acquisition-driven growth model. Roughly $439.6M was deployed on acquisitions in Q1 2026, funded partly by debt and contributing to a $207.7M net cash decrease, while Q2 2026 free cash flow of $68.5M was dampened by a $34.1M working-capital drag. Debt-to-equity of 0.224 and interest coverage of 13.25x are comfortable today, but a continued M&A cadence means external financing remains part of the model, and ROE of 10.9% and ROA of 6.8% are respectable rather than exceptional — leaving limited margin for integration missteps. Revenue concentration in HVAC, the majority segment, means a cyclical downturn in commercial construction would hit the core top line directly.
Market and competitive risks are dominated by valuation compression. The trailing PE of 39.2x sits near the top of the stock's 19x–41x historical band, PS of 4.22x and EV/EBITDA of 20.0x are premium multiples for a construction-materials/industrial name, and PEG of 2.24 offers no growth-adjusted cushion. With a beta of 1.241, the stock is roughly 24% more volatile than the market, amplifying any sector rotation out of cyclical industrials; the -34.5% six-month relative underperformance versus SPY already demonstrates this sensitivity. The absence of recent news means no fresh catalyst has emerged to break the negative momentum, and the wide $215–$310 analyst target range (44% spread) itself signals conviction gaps that can feed further de-rating.
The worst-case scenario is a double-hit: HVAC orders decelerate as the cycle matures, acquired revenue fails to integrate at expected margins, and the $9.58 consensus EPS is cut, compressing both the estimate and the multiple simultaneously. In that chain, the stock would likely break below the $155.86 52-week low — only 2.8% below the current $160.33 — with little technical support beneath, and could approach the analyst low target of $215 only in a recovery, meaning downside is technically open-ended. Quantifying realistically, a retest of the 52-week low implies roughly -3% from here, but the -35.06% max drawdown illustrates how far sentiment-driven selling can run; a move to the $120–$130 area would represent a -20% to -25% loss from current levels and is plausible if forward estimates are cut by 15–20%.
FAQ
Ranked by severity: first, estimate risk — the 39.2x trailing PE and 4.22x PS leave no cushion if the $9.58 consensus EPS is cut, creating a double-hit of falling estimates and multiple compression. Second, technical/momentum risk — the stock is 2.9% above its $155.86 52-week low with -34.5% six-month relative underperformance versus SPY, and a break below that level would likely trigger further selling with little support beneath. Third, acquisition and leverage risk — roughly $439.6M was deployed on Q1 2026 acquisitions funded partly by debt, with a $207.7M net cash decrease and a $34.1M working-capital drag on Q2 FCF, so integration missteps would hit both earnings and the balance sheet. Fourth, cyclical and macro risk — HVAC is the majority revenue segment, and with beta of 1.241 the stock is ~24% more volatile than the market, amplifying any construction-cycle downturn or sector rotation out of industrials.
The 12-month outlook has three scenarios: a 25% bull case targeting $253–$310 (aligned with the analyst average and high targets) if a Q3 beat validates the $9.58 EPS and the multiple re-rates; a 50% base case targeting $175–$215 if fundamentals hold but the stock grinds sideways-to-higher while awaiting proof on organic growth; and a 25% bear case targeting $120–$156 if HVAC demand decelerates and consensus EPS is cut 15–20%, breaking the $155.86 low. The base case is most likely, with the key assumption being that forward EPS of $9.58 is broadly achieved, keeping the forward PE in the 16x–20x range. The wide $215–$310 analyst target spread (44%) itself signals high uncertainty, so the forecast should be treated as a probability distribution rather than a point estimate.
The answer depends entirely on which earnings base you trust. On trailing fundamentals the stock is expensive: PE of 39.2x sits near the top of its own 19x–41x historical band, PS of 4.22x and EV/EBITDA of 20.0x are premium multiples for a construction-materials/industrial name, and PEG of 2.24 offers no growth-adjusted cushion. On forward earnings it looks reasonably valued: the 16.4x forward PE (based on $9.58 consensus EPS) is below the broader market and represents 58% compression from the trailing multiple. The market is effectively pricing in doubt that the consensus estimate is achievable — if it is, the stock is undervalued relative to its history and peers; if estimates are cut, the trailing premium reasserts itself. Net verdict: fairly valued on forward earnings, expensive on trailing fundamentals, with the valuation implying the market expects either an earnings miss or a prolonged HVAC slowdown.
From a risk/reward perspective, SPXC offers an unusually wide gap between fundamentals and price: revenue grew 22.9% YoY to $679.0M with operating margin expanding to 17.2%, yet the stock trades 58% below its $253.38 average analyst target with a 'strong buy' consensus. The forward PE of 16.4x versus 39.2x trailing suggests the market is pricing in an earnings disappointment that has not materialized. However, the stock sits just 2.9% above its $155.86 52-week low with -27.1% three-month momentum, so the biggest downside risk is a break below that level triggering further selling. It is a good buy for patient investors with a 12–18 month horizon who can tolerate beta of 1.241 and a -35.06% max drawdown, ideally accumulating in tranches and waiting for a reclaim of $175 as confirmation. It is not a good buy for short-term traders or those needing income, given the zero dividend.
SPXC is better suited to a medium-to-long-term holding period of at least 12–18 months rather than short-term trading. The company is in a growth stage with 22.9% revenue growth and expanding margins, but it pays no dividend (payout ratio 0) and has a beta of 1.241 with a -35.06% max drawdown, making it unsuitable for income investors or those with low volatility tolerance. Earnings visibility is moderate — the 58% gap between trailing and forward PE means the market has low confidence in near-term estimates, and the accelerating downtrend (-27.1% over three months) argues against short-term entry. A concrete approach: accumulate in tranches over 6–12 months, using a reclaim of $175 as confirmation of a bottom, and reassess after the Q3 2026 print; short-term traders should wait for that technical signal rather than catching the falling knife near the $155.86 low.